CNBC September 12, 2024
Ashley Capoot

Key Points

– Noom on Thursday announced it is offering users access to compounded semaglutide as part of a new weight loss product starting at $149.

– The digital health company already offers branded GLP-1s through its platform, but it wanted to give patients access to a cheaper alternative.

– Noom said its new offering also supports patients if they decide they want to taper off the medication.

Digital health company Noom on Thursday announced it will offer a compounded GLP-1 drug as part of a new weight loss product that starts at $149.

The treatment will feature compounded semaglutide, the same active ingredient in Novo Nordisk‘s blockbuster obesity and diabetes drugs Wegovy and Ozempic. Noom has offered weight...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Digital Health, Pharma / Biotech, Technology
Connecting for Health at Home: A Unified Field Theory from #CES2025 (On Samsung, Withings, and Panasonic)
2025 Tech Trends: 4 Healthcare IT Focus Areas
Digital Health Funding Decline in 2024: Rise of the Mega Funds
Digital Health Unplugged: The future of mental health technology
Solera Health Secures $40M to Expand Access to Digital Healthcare

Share This Article